TEI Biosciences Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From TEI Biosciences Inc.
Integra LifeSciences surged to industry-leading 12% sales growth in 2016, and that's before it prepares to consolidate two of the biggest acquisitions in its history. What is the strategy behind the success of the specialty surgery, orthopedics and tissue tech company that is looking at another double-digit sales uplift in 2017?
Mega-deals and innovative technologies have transformed advanced wound care into a robust, high-tech market in the US. While regulatory and reimbursement challenges persist, opportunities in adjacent spaces and under-penetrated OUS markets represent fertile ground for advanced wound care expansion.
The US market for orthopedic extremities and soft-tissue repair products will grow by $2.2 billion over the next five years, according to a global market report from Medtech Insight. Major factors contributing to the strong growth of this market include: the expanding elderly demographic, an increase in the number of active adults who are prone to physical injuries, and improvements in biological material and implants that reduce complications and improve quality of life.
$1.4 billion in Q3 device financing was slightly lower than Q2's $1.8 billion with just one IPO versus Q2's seven. Acquisitions reached a high of $23 billion and diagnostics financing increased 30% over Q2 to $1 billion, while M&A activity at $1.2 billion showed a sharp decline from the previous quarter's $15.6 billion.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.